<DOC>
	<DOCNO>NCT00798096</DOCNO>
	<brief_summary>Patients meet specific inclusion exclusion criterion enrol two stage , 19 patient Stage 1 36 patient Stage 2 . Stage 2 enroll 4 patient exhibit response Week 8 later study . All enrol patient treat Fostamatinib Disodium disease progression . Efficacy assess tumor measurement use CT PET ( indicate ) scan physical exam baseline , scan physical exam disease-involved area every 8 week progression . Safety assess periodic physical exam , clinical laboratory study , adverse event . All patient follow-up visit 30 day follow last study drug treatment . Blood sample PK assessment obtain patient enrolled Stage 1 protocol define interval .</brief_summary>
	<brief_title>Efficacy Safety Study Fostamatinib Disodium Tablets Treat T-Cell Lymphoma</brief_title>
	<detailed_description>Up 61 patient ( male female ) meeting inclusion exclusion criterion enrol trial two stage . All enrol patient treat R788 200 mg PO bid disease progression . In initial stage study , total 19 patient enrol treated Fostamatinib Disodium . Should least 4 patient exhibit response Week 8 later study , second stage 36 patient open enrollment . Efficacy assess CT PET scan ( indicate ) physical exam baseline , CT scan physical exam disease-involved area every 8 week progression . Safety assess periodic physical exam , clinical laboratory study , adverse event . All patient follow-up visit 30 day follow last study drug treatment . Blood sample PK assessment obtain patient enrolled Stage 1 protocol-defined interval . Patients accessible tumor tissue ask undergo biopsy fresh tissue sample assessment Syk activity tumor tissue . Archived tissue sample initial diagnostic biopsy recent biopsy lymphoma obtain event fresh tumor biopsy obtain . Patients accessible tumor tissue ask consent second tumor biopsy Week 8 , assess impact Fostamatinib Disodium treatment activity Syk downstream marker . All baseline fresh archive tumor tissue sample undergo central pathology review confirm diagnosis TCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<criteria>Patients must give write informed consent participate study sign IRB/ECapproved Informed Consent Form ( ICF ) prior admission study . Males female , 18 year age old . Patients must histologically prove Tcell lymphoma ( TCL ) . Patients must document disease progression receive least one prior therapeutic regimen must patient know curative therapy exists . Patient history , concurrent , clinically significant illness , medical condition laboratory abnormality , investigator 's opinion , could affect conduct study . Has Bcell lymphoma , primary CNS lymphoma , know lymphomatous involvement CNS , NK/Tcell leukemia/lymphoma . Has uncontrolled poorly control hypertension . Has recent ( within 1 month prior Day 1 ) serious surgery uncontrolled infectious disease . Has concurrent malignancy require treatment . Has know positive test Hepatitis B surface Ag , Hepatitis C , HIV . Has laboratory abnormality . Has difficulty swallow malabsorption . Has ECOG performance status &gt; 2 . Has recover adverse effect relate last prior therapy lymphoma . Has allotransplantation within 90 day prior Day 1 treatment . Has treat CYP3A4 inducer/inhibitor within 3 day prior Day 1 treatment expect require treatment CYP3A4 inducer/inhibitor course study . Has receive systemic steroid dose great equivalent 10 mg/day prednisone within 7 day prior Day 1 treatment . Has receive investigational therapy within 5 halflives agent 2 week Day 1 treatment , whichever long . Is female childbearing potential unless menopausal , surgically sterile , willing use effective method birth control , ( oral contraceptive , mechanical barrier , longacting hormonal agent ) , study 30 day thereafter . Is pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>T Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>